Financing ·
Halozyme raises $1.5B via convertible notes due 2033 to fund $652.5M buybacks of existing debt
HALOHalozyme Therapeutics, Inc.
On September 22, 2026, Halozyme Therapeutics, Inc. completed the sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including a $200.0 million option exercise by initial purchasers. The company received net proceeds of approximately $1,471.1 million after deducting discounts and offering expenses. Approximately $187.5 million was used to fund Capped Call Transactions with an initial cap price of $208.39 per share to mitigate potential dilution. Additionally, the company intends to use a portion of the net proceeds to repurchase approximately $151.7 million of its 0.25% convertible senior notes due 2027 and $220.0 million of its 1.00% convertible senior notes due 2028, with total estimated repurchase costs of approximately $652.5 million including accrued interest. The remaining proceeds are designated for general corporate purposes, including working capital, capital expenditures, potential acquisitions, and strategic transactions. Halozyme Therapeutics operates in the biotechnology industry, focusing on drug delivery technologies and oncology treatments.